[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"vaccination-infection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:vaccination-infection":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,46,77],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100585845","study-of-the-impact-of-time-of-vaccination-on-response-to-influenza-vaccine-in-patients-with-chronic-renal-failure-100585845",false,"NCT06907667","Study of the Impact of Time of Vaccination on Response to Influenza Vaccine in Patients With Chronic Renal Failure","Study of the Impact of Time of Vaccination on Response to Influenza Vaccine in Patients With Chronic Renal Failure - CHRONOVAX 2","CHRONOVAX2","Inclusion Criteria:\n\n* Chronic renal failure patient at stage 4 or 5 (i.e. estimated GFR \\\u003C 30mL\u002Fmin\u002F1.73m2); or Dialysis patient; or renal transplant patient regardless of GFR;\n* Age ≥ 18 years;\n* Indication for influenza vaccination;\n* Express free and informed consent.\n\nExclusion Criteria:\n\n* Known hypersensitivity to influenza vaccine or egg proteins;\n* Previous influenza vaccination for the current season;\n* Current infection;\n* Current acute illness;\n* Treatments with a major impact on vaccine response:\n* Treatment of rejection within the previous 3 months;\n* Renal transplantation with induction performed within the previous 6 months;\n* Immunosuppressive treatment including CTLA4 agonist, complement inhibitor, anti-CD20;\n* Treatments that may distort the serological response: Polyvalent immunoglobulin infusion within the preceding 3 months;\n* Vulnerable persons (minors, adults under guardianship or trusteeship, persons deprived of their liberty, persons unable to speak French);\n* Subjects not affiliated to Social Security.","ALL","18 Years","100 Years",{"count":21,"type":22},735,"ESTIMATED","INTERVENTIONAL",[25],"NA","Immune response to influenza vaccine in patients with chronic renal insufficiency.",[28],"Vaccination; Infection",[30,31,32],"Influenza","chronic renal insufficiency","Vaccination","RECRUITING","2026-05-13",{"date":36,"type":37},"2026-05-15","ACTUAL",{"date":39,"type":37},"2025-09-03",{"date":41,"type":22},"2027-09",{"name":43,"class":44},"Centre Hospitalier Universitaire de Nice","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":17,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":59,"conditions":60,"keywords":63,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":45},"100437020","the-immune-responses-after-hepatitis-b-revaccination-doses-in-a-young-cohort-100437020","NCT04970836","The Immune Responses After Hepatitis B Revaccination Doses in a Young Cohort","IRHBRVD","Inclusion Criteria:\n\n1. The actual age at the time of admission was higher than 20 years old and birth year after 1987\n2. Born in Taiwan and had received a full course of hepatitis B vaccines at least three doses at infant period.\n3. Those who have tested negative for hepatitis B surface antibody and surface antigen at baseline\n4. Have never been vaccinated against hepatitis B in childhood and adolescence by questionnaire\n5. Consent to administer 1-2 doses of hepatitis B vaccine according to the assigned group after sharing decision making process\n6. In good health\n\nExclusion Criteria:\n\n1. Those who were previously allergic to hepatitis B vaccine or its components (such as yeast)\n2. Those who have been vaccinated against hepatitis B during childhood and adolescence\n3. Those who have a positive test for hepatitis B surface antibody or a positive test for hepatitis B surface antigen",true,"20 Years","36 Years",{"count":57,"type":22},240,[25],"This prospective cohort study aims to provide the evidence-based clinical guide to help decide the revaccination doses of hepatitis B vaccine that the high-risk young adults without hepatitis B seroprotective antibodies (anti-HBs titer\\\u003C10 mIU\u002FmL) need to take.",[61,28,62],"Hepatitis B","Preventable Disease, Vaccine",[64,65,66,67],"hepatitis B vaccine","revaccination","young adult","booster","2025-03-17",{"date":70,"type":37},"2025-03-20",{"date":72,"type":37},"2021-08-01",{"date":74,"type":22},"2027-12-31",{"name":76,"class":44},"National Taiwan University Hospital",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":53,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":45},"100553907","triage-survey-for-infectious-disease-eligibility-100553907","NCT06492187","Triage Survey for Infectious Disease Eligibility","Triage Survey for Infectious Disease Eligibility (SWIFT-ID-101)","Inclusion Criteria:\n\n\\- 1. Participant or Legally Authorized Representative has signed an ICF prior to study-specific procedures being performed.\n\n2\\. Participant is at least 18 years old.\n\nExclusion Criteria:\n\n1. Participants are pregnant, breast-feeding, or planning to become pregnant.\n2. History of a clinically significant illness which in the investigator's opinion may impact participant safety or the ability to analyze study results or makes them unsuitable for the study for another reason.\n3. Current or recent moderate or severe substance use disorder impacting their ability to follow study related procedures.\n4. Reported history of coagulopathy or bleeding disorder considered a contraindication to phlebotomy.\n5. Any condition that in the investigator's opinion makes a participant unsuitable for the clinical trial study.\n6. Currently employed by Swift Clinical Research Group, Inc. or any of its subsidiaries, including Brooklyn Clinical Research, or a first-degree relative of an employee.",{"count":85,"type":22},10000,"OBSERVATIONAL","SWIFT-ID-101 is a single site survey study designed to assess potential participants' eligibility to screen for industry-sponsored clinical trials for diagnosis, treatment, or prevention of infectious diseases such as in the areas of HIV, vaccines, and other infectious-diseases areas. A physician will oversee the informed consent process, after which participants will be surveyed on demographics, medical\u002Fsurgical history, physical examination, comorbidities, and any current symptoms. Informed consent will be done electronically (preferable) or on paper. Informed consent may be done in-person or remotely, depending on patient preference. Information related to HIV, hepatitis B and C, other infectious diseases, or substance use disorder will also be obtained if applicable. Site staff may collect vital signs, fingerpick testing, urine drug screens, blood draws, EKG, and pregnancy tests. Some testing may be recommended in a fasting condition. A doctor will review medical history and results of the above evaluations with the participant to determine study suitability via clinical interview. The doctor may reach out to the patient's current treating physicians, other providers, and pharmacies to determine eligibility for clinical trials. A follow-up phone call may be needed to discuss testing results and\u002For trial eligibility. If a participant is deemed eligible for future trials and if the participant remains interested, counseling on contraception requirements for trials will be discussed.",[28,89,90],"HIV-1-infection","Infectious Disease","2024-07-01",{"date":93,"type":37},"2024-07-09",{"date":95,"type":37},"2024-06-28",{"date":97,"type":22},"2029-01-28",{"name":99,"class":100},"Brooklyn Clinical Research","NETWORK"]